Coronation Fund Managers 13F: Adds $4.9M to TMO Stake

On October 27, 2026, Coronation Fund Managers boosted its position in Thermo Fisher Scientific Inc. (TMO) by 7,220 shares, bringing its total to 45,019 shares valued at approximately $30.4 million. This information comes from the fund's latest Form 13F filing with the SEC.

In the filing, Coronation Fund Managers reported a 19.1% increase in its stake. The fund's total reported value in Thermo Fisher now stands at about $1.75 billion, with this position making up 1.73% of its overall portfolio. The fund ranks 16th among its holdings.

TMO Thermo Fisher Scientific Inc.

$693.02 ▲ +17.29% year to date

1M 3M YTD

Daily close · Oct 27, 2026

Other Institutional Activity in Thermo Fisher Scientific

Several other funds have also adjusted their positions in Thermo Fisher. Verdence Capital Advisors grew its holdings by 4,673 shares, bringing its total to 19,919 shares worth about $13.4 million. Asset Management One increased its stake by 19,813 shares, totaling 219,346 shares valued at approximately $148.1 million. Franklin Resources, Inc. added 458,515 shares, raising its total to 7,271,514 shares worth about $5.0 billion.

Thermo Fisher Scientific Inc. Stock Holds Steady

Thermo Fisher stock closed at $693.02 on October 27, 2026. The recent price is around $684.89, which is about 1.2% below the closing price. The shares are currently trading well above their 200-day moving average by 24.5% and above their 50-day moving average by 5.5%.

Recent Earnings

Thermo Fisher Scientific reported trailing twelve-month revenue of approximately $47.4 billion with a net margin of 14.9%. The company is scheduled to announce its next earnings on January 28, 2027.

Insider Buying and Selling at Thermo Fisher Scientific Inc.

Recently, several insiders sold shares in Thermo Fisher. On August 19, 2026, Lisa P Britt, an officer, sold 11,440 shares for about $7.0 million. CEO Marc N Casper sold 20,000 shares on August 21, 2026, valued at approximately $12.6 million. Another sale by Casper involved 275 shares on August 24, 2026, totaling about $172,439. President Gianluca Pettiti sold 4,133 shares on August 31, 2026, valued at around $2.5 million.

Analysts Set New Price Targets

On October 22, 2026, Barclays maintained its Overweight rating on Thermo Fisher with a price target of $775. RBC Capital also maintained a Sector Perform rating with a target of $730. Other firms such as TD Cowen and Citigroup have maintained their Buy ratings with targets of $810 and $800, respectively.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products. The company operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services.

Bottom Line

Investors should keep an eye on Thermo Fisher's upcoming earnings report on January 28, 2027, as well as any further changes in institutional holdings. The recent boost by Coronation Fund Managers indicates ongoing confidence in the company's performance.